重要内容提示： 证券代码：603014 证券简称：威高血净 公告编号：2026-008 山东威高血液净化制品股份有限公司关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2026年第一次临时股东会 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026年2月27日至2026年2月27日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的9:15- 15:00。 （六）融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所上市公司自律监管指引第1号一规范运作》等有关规定执行。 （七）涉及公开征集股东投票权 无 二、会议审议事项 本次股东会审议议案及投票股东类型 ■ （二）股东会召集人：董事会 （三）投票方式：本次股 ...

一、召开会议的基本情况 （一）股东会类型和届次 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603014 证券简称：威高血净 公告编号：2026-008 山东威高血液净化制品股份有限公司 关于召开2026年第一次临时股东会的通知 2026年第一次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 召开地点：山东省威海市威高西路 7 号威高血液净化办公楼 6 楼 601 会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 27 日至2026 年 2 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六）融资融 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price while maintaining a stable financing balance and positive revenue growth [1][2]. - As of February 6, Weigao Blood Purification's stock price decreased by 0.69%, with a trading volume of 33.35 million yuan. The net financing purchase on that day was 1.54 million yuan, with a total financing and securities balance of 123 million yuan [1]. - The company reported a revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45%, and a net profit attributable to shareholders of 341 million yuan, which is a 7.92% increase year-on-year [2]. Group 2 - The company has a significant portion of its revenue coming from consumables, accounting for 77.55%, while equipment contributes 18.25%, and other sources make up 2.35% and 1.85% respectively [1]. - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Core Viewpoint - The company has successfully redeemed structured deposit products amounting to 235 million RMB, generating a total return of 364,300 RMB from these investments [1][2]. Group 1: Redemption Details - The total redemption amount for the structured deposit products is 235 million RMB [1]. - The structured deposit products were purchased from Weihai Bank and Minsheng Bank, with amounts of 180 million RMB and 55 million RMB respectively [1]. - The total return from the redeemed products is 364,300 RMB [2]. Group 2: Cash Management Status - As of the announcement date, the company has a remaining balance of 240 million RMB in unused raised funds for cash management, which is within the authorized limits set by the board [2]. - The company is authorized to use up to 740 million RMB of temporarily idle raised funds for cash management, ensuring that it does not affect the construction and use of the raised funds [1].

证券代码：603014 证券简称：威高血净 公告编号：2026-007 山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、截至本公告日，授权有效期内使用募集资金进行现金管理的情况 截至本公告披露日，公司使用闲置募集资金进行现金管理未到期余额为 24,000.00 万元人民币，未超过董事会授权使用闲置募集资金进行现金管理的金额范 围和投资期限。 单位：万元 | 序 | 购买 | 签约银行 | 产品名 | 认购金额 | 起息日 | 到期日 | 预期年化收益率 | 赎回金额 | 实际收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | 称 | | | | | | 益 | | 1 | 威高 血净 | 威海银行股 份有限公司 东城支行 | 结构性 存款 | 18,000.00 | 2026/1/1 | 2026/1/31 | 0. ...

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% equity of Weigao Puri Pharmaceutical Packaging Co., Ltd. [3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [2][3] - The company was established on December 27, 2004, and was listed on May 19, 2025 [3][7] - The revenue composition of the company includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [7] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45% [7] - The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [7] - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [8] Market Activity - On February 4, the stock price of Weigao Blood Purification increased by 0.17%, with a trading volume of 36.6268 million yuan and a turnover rate of 2.32%, resulting in a total market capitalization of 16.815 billion yuan [1] - The stock has seen a net outflow of 2.0387 million yuan from major investors today, with a continuous reduction in holdings over the past three days [4][5] Technical Analysis - The average trading cost of the stock is 41.25 yuan, with recent reductions in holdings slowing down [6] - The current stock price is fluctuating between a resistance level of 40.53 yuan and a support level of 39.80 yuan, indicating potential for range trading [6]

2025 年，在资本市场高质量发展与科技创新双向赋能下，山东上市公司呈现稳中有进、结构优化的发展态势，为全省经济高质量发展注入强劲动力。 核心发展态势 截至 2025 年末，山东上市公司达 311 家，总市值 4.91 万亿元，同比增长 35.82%，首现超 5000 亿元市值企业（中际旭创）。股权融资表现亮眼，IPO 融资 34.26 亿元，同比增长 23.02%；股权再融资 214.75 亿元，同比激增 534.23%，定向增发为主要融资方式。市场生态持续净化，全年受处罚次数和金额分别下 降 46.21% 和 74.30%。 对比与展望 与粤苏浙相比，山东上市公司数量、融资规模仍有差距，但板块指数涨幅 44.25% 居全国第三，新质生产力布局成效初显。随着新旧动能转换推进，山东上 市公司在科技研发与产业创新融合上持续发力，未来将进一步依托资本市场实现高质量发展。 融资结构优化：5 家 IPO 企业集中在医药生物、电子等高新领域，3 家为专精特新企业，新股上市首日平均涨幅超 6 倍，赚钱效应显著。 市值与行业变革：烟台上市公司市值增长 94.15%，占全省增量 56.67%，跃居省内首位；通信行业市值首超基 ...

Group 1 - The core issue revolves around a bribery case involving a sales employee from Weigao Co., which has exposed a network of corruption spanning nine years, involving kickbacks totaling 1.1912 million yuan across 18 departments in hospitals [2] - Weigao Co. is also involved in a controversial asset maneuvering operation, where 8.5 billion yuan worth of assets were transferred, raising concerns about inflated valuations and financial practices [2] - The bribery case reflects broader issues within the industry, highlighting systemic problems in compliance and ethical conduct [2] Group 2 - Weigao Blood Purification, which recently went public, announced plans to acquire Weigao Co.'s subsidiary, Weigao Purui, for 8.511 billion yuan, representing a nearly 200% increase in valuation [3] - The acquisition is strategically beneficial as Weigao Purui is projected to generate a net profit of 581 million yuan in 2024, surpassing Weigao Blood Purification's own earnings [3] - The company's net profit margin has declined from 20.3% in 2022 to 15.91% in the first half of 2025, indicating pressure from price reductions in low-value medical supplies [3] Group 3 - The company is advised to focus on product innovation and compliance rather than engaging in financial maneuvers, as the core competitiveness in the medical industry lies in quality and technological barriers [4]

证券代码：603014 证券简称：威高血净 公告编号：2026-006 山东威高血液净化制品股份有限公司 关于发行股份购买资产暨关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、本次交易的历史披露情况 为了维护投资者利益，避免对公司股价造成重大影响，根据上海证券交易所（以 下简称"上交所"）的相关规定，经公司申请，公司股票（证券简称：威高血净， 证券代码：603014）自 2025 年 10 月 20 日（星期一）开市起停牌，具体内容详见公 司于 2025 年 10 月 18 日披露的《山东威高血液净化制品股份有限公司关于筹划发行 股份购买资产暨关联交易事项的停牌公告》（公告编号：2025-033）以及 2025 年 10 月 25 日披露的《山东威高血液净化制品股份有限公司关于筹划发行股份购买资产暨 关联交易事项停牌的进展公告》（公告编号：2025-034）。 2025 年 10 月 31 日，公司召开了第二届董事会第十七次会议，审议通过了《关 于<山东威高血液净化制品股份有限公司发行股份购买资产暨 ...